MET and non-small cell lung carcinoma: In NSCLC, for instance, MET genomic alterations, such as MET gene amplification or MET exon 14 mutations, are present in <5% of patients,13, 14 whereas 30%–50% of patients have tumors that overexpress c‐Met in the absence of MET genomic alterations.33